Because GLP-1s may improve inflammation, gut-related symptoms, and insulin resistance, they may help some women with bloating and endo belly symptoms
A 2023 analysis published in JAMA Internal Medicine (Blumenthal et al.) examined mental health outcomes in patients using GLP-1 receptor agonists and found no significant increase in adverse psychiatric events compared to control groups, offering reassurance about the general safety profile of these medications in patients managing mental health conditions
That, my dear, is called the Sunday Scaries
Persistent fatigue despite adequate sleep and nutrition suggests potential underdosing or inadequate caloric intake
Akkermansia muciniphila (AKK), a mucin-degrading gut probiotic, has gained attention for its therapeutic potential in metabolic and immune-related diseases in recent years [20], and is considered to have the potential for the treatment of MASLD [21, 22]
The complexities arise from Section 503A of the Federal Food, Drug, and Cosmetic Act, which relates to the necessary conditions for drug compounding.20 The rules concerning the compounding of therapeutic peptides state that they must come from accredited compounding pharmacies, and the compounded drug must either be compounded from an existing FDA-approved drug product or use drug products included on the 503A bulks list (i.e., the FDAs roster of compoundable substances.)21 But many therapeutic peptides dont satisfy either of the 503A conditions